CBT heads into its Q2 2026 earnings release — due today — with options traders leaning unusually constructive for a specialty chemicals name facing genuine top-line headwinds.
The put/call ratio has dropped sharply over the past two weeks, moving to 0.31 from readings above 0.47 in early-to-mid April. That shift is half a standard deviation below the 20-day average of 0.36 — a notable tilt toward calls. The move coincides with a 4% one-day price jump on May 5 that carried the stock to $78.93. Year-to-date, CBT is up nearly 17%, outpacing most of its commodity chemicals peers. Close peer FUL fell 7% on the week, while NGVT and AVNT each dropped more than 3% — making Cabot's resilience stand out.
Short sellers have grown less comfortable with that outperformance. Short interest has climbed 17% over the past month to 5.7% of free float, with the weekly pace accelerating — up roughly 1.8% over the last five sessions. The ORTEX short score crossed above 50 for the first time in recent weeks, signalling that the balance of short-selling signals has tipped marginally negative. That said, the borrow market remains relaxed: cost to borrow holds near 0.45% and availability is ample, meaning there is no squeeze pressure building to force shorts to cover.
The analytical community is divided, and the most recent moves lean cautious. In early February, Mizuho downgraded CBT to Neutral and cut its target to $75 — the stock now trades above that level. UBS held its Neutral rating but moved its target to $81. The Street's mean target is $78.80, sitting essentially in line with today's close. That leaves almost no premium for upside in the consensus view. The valuation picture adds nuance: CBT trades at roughly 6.9x EV/EBITDA with a P/E near 11.8x — undemanding multiples for a company with 20% EBITDA margins and a dividend-score percentile rank of 95. The most recent quarterly revenue came in at $849m, down 11% year-on-year, a decline that has driven the bear case that carbon black and specialty fluids demand remains under pressure from softer industrial activity.
The print will therefore test whether Cabot's margin discipline and emerging signs of volume recovery are enough to justify the stock trading back at analyst target — or whether the building short interest reflects a more persistent demand softness the options market is currently choosing to look through.
See the live data behind this article on ORTEX.
Open CBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
